Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus CHOLEDYL SA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus CHOLEDYL SA.
AEROLATE III vs CHOLEDYL SA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Category C
Category C
Bronchodilator
Bronchodilator